Dalcetrapib

Base Information

• Chemical Name: Dalcetrapib
• CAS No.: 211513-37-0
• Molecular Formula: C₂₃H₃₅NO₂S
• Molecular Weight: 389.602
• European Community (EC) Number: 816-493-8
• UNII: 3D050LIQ3H
• DSSTox Substance ID: DTXSID70943475
• Nikkaji Number: J1.392.046J
• Wikipedia: Dalcetrapib
• Wikidata: Q5210285
• NCI Thesaurus Code: C81529
• Metabolomics Workbench ID: 153216
• ChEMBL ID: CHEMBL313006
• Mol file: 211513-37-0.mol

Synonyms:dalcetrapib;JTT 705;JTT-705;JTT705;RO-4607381;RO4607381;S-(2-((1-(2-ethylbutyl)cyclohexane)carbonylamino)phenyl) 2-methylpropanethioate

Chemical Property of Dalcetrapib

Chemical Property:

• Melting Point: 63-63.5 °C
• Boiling Point: 528.912 °C at 760 mmHg
• PKA: 13.95±0.70(Predicted)
• Flash Point: 273.676 °C
• PSA: 71.47000
• Density: 1.066 g/cm³
• LogP: 6.74960
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• Solubility.: insoluble in H2O; ≥12.7 mg/mL in DMSO; ≥80.2 mg/mL in EtOH
• XLogP3: 7.1
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 3
• Rotatable Bond Count: 9
• Exact Mass: 389.23885053
• Heavy Atom Count: 27
• Complexity: 481

Purity/Quality:

98%,99%, ^*data from raw suppliers

Dalcetrapib ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
• Recent ClinicalTrials: Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
• Recent EU Clinical Trials: A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-GenE trial
• Uses: Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Dalcetrapib is a drug undergoing trials for the treatment of cardiovascular disease, dyslipidemia, peripheral arterial disease (PA D). Dalcetrapib is a cholesteryl ester transfer protein (CETP) inhibitor. Dalcetrapib is a drug undergoing trials for the treatment of cardiovascular disease, dyslipidemia, peripheral arterial disease (PAD).

Technology Process of Dalcetrapib

There total 8 articles about Dalcetrapib which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 98.2%

2-Methylpropionic anhydride (97-72-3) + bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide (211513-15-4) → dalcetrapib (211513-37-0)

Guidance literature:

With hydrogen; 4.78percent nPdnAl₂O₃/Al₂O₃; In toluene; at 80 ℃; for 5h; under 3750.38 Torr; Product distribution / selectivity; Autoclave;

Reference yield: 97.0%

isobutyryl chloride (79-30-1) + Dalcetrapib (211513-21-2) → dalcetrapib (211513-37-0)

Guidance literature:

With pyridine; at 20 ℃; for 1h;

DOI:10.1021/jm000224s

Reference yield:

1-(2-ethyl-butyl)-cyclohexanecarboxylic acid (381209-09-2) → dalcetrapib (211513-37-0)

Guidance literature:

Multi-step reaction with 4 steps

1: 38 percent / oxalyl chloride / CH₂Cl₂ / 1 h / 20 °C

2: pyridine / 100 °C

3: Ph₃P; H₂O / dioxane / 1 h / 50 °C

4: 97 percent / pyridine / 1 h / 20 °C

With pyridine; oxalyl dichloride; water; triphenylphosphine; In 1,4-dioxane; dichloromethane; 1: Chlorination / 2: Acylation / 3: Reduction / 4: Acylation;

DOI:10.1021/jm000224s

upstream raw materials:

isobutyryl chloride

Dalcetrapib

1-(2-ethyl-butyl)-cyclohexanecarboxylic acid

2-ethyl-1-bromobutane

Refernces

• 1、 -. "PROCESS FOR THE PREPARATION OF AROMATIC THIOL DERIVATIVES BY HYDROGENATION OF DISULFIDES". Page/Page column 27. . Retrieved 2012/06/30.
• 2、 -. "NOVEL PROCESS". Page/Page column 21, 22. . Retrieved 2011/02/24.